Sofinnova Partners’ portfolio company Cerenis Therapeutics successfully raises €53.4 M on its Euronext listing

• Actively backed by international institutional investors, the IPO was 3.8 times oversubscribed
• Cerenis’ market capitalization reaches €226 M

Paris, France – March 26th 2015. Sofinnova Partners, a Paris-based venture capital firm, today announced the successful IPO of its portfolio company Cerenis Therapeutics which raised €53.4 M on Euronext Paris (on the B compartment). Sofinnova Partners has been the main shareholder since the start of the company in 2005. The initial public offering was 3.8 times oversubscribed and significantly backed by institutional international investors.

Specialized in the treatment of cardiovascular and metabolic diseases, Cerenis Therapeutics which is based near Toulouse in France, is developing a portfolio of novel HDL therapies. HDL, High-density Lipo-protein, is the primary facilitator of the reverse lipid transport, pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body. Through its innovative therapeutic platform, the company is developing a recombinant HDL particle that allows to rapidly regress atherosclerotic plaque and reduce the risk of cardiovascular events.

Denis Lucquin, Managing Partner at Sofinnova Partners and Cerenis Therapeutics’ Board Member since 2005, said: « Cerenis completed one of the most remarkable IPOs in France for a long time. As historical and still main investor after the listing, we are thrilled by the quality of this new financing round. This success attests of the quality of the collaboration Sofinnova Partners established with Jean-Louis Dasseux, CEO and Founder, since the inception of the company. The key role played by Richard Pasternak, M.D., Chairman of the Board of Directors, was also decisive”.

Cerenis Therapeutics issued 4 207 316 shares allowing a capital increase of €53.4 M. On the basis of 17 788 878 shares to be traded on Euronext Paris, at €12.70 per share, Cerenis Therapeutics’ market capitalization reaches €226 M. Trading will begin on March 30th. 2015 under the symbol « CEREN ». Please refer to the company’s press release for additional information on the listing.

About Sofinnova Partners
Sofinnova Partners is an independent venture capital firm based in Paris, France. For more than 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside key entrepreneurs in the Life Sciences industry around the globe. With over €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.
For more information, please visit: www.sofinnova.fr

For more information on Cerenis Therapeutics, please visit: www.cerenis.com